Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01503866 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Healthy Male Subjects
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01503866: Completed Phase 1 study, sponsored by Biogen.
NCT01503866 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01503866, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the absorption and excretion kinetics of bardoxolone methyl and to determine and characterize metabolites present in plasma, urine and feces in men following a single oral does or 20 mg of \[14C\]-bardoxolone methyl.
Interventions
- DRUG bardoxolone methyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-12-01 |
| Est. Completion | 2011-12-31 |
| Phase | Phase 1 |
What the finished NCT01503866 record still lists
NCT01503866 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which bardoxolone methyl is the first listed.
NCT01503866 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01503866 about?
NCT01503866 is a clinical study titled "A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Healthy Male Subjects". The purpose of this study is to determine the absorption and excretion kinetics of bardoxolone methyl and to determine and characterize metabolites present in plasma, urine and feces in men following a single oral does or 20 mg of \[14C\]-bardoxolone methyl.
What is the current status of trial NCT01503866?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2011-12-01. Estimated completion is 2011-12-31.
What interventions are being tested in trial NCT01503866?
The interventions under investigation include: bardoxolone methyl (DRUG).
Who is sponsoring clinical trial NCT01503866?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01503866's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI